Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
about
Immunotherapy in Multiple Myeloma Using Cancer-Testis AntigensAdoptive T-cell therapy for LeukemiaMultiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.T cell-based targeted immunotherapies for patients with multiple myeloma.Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cellsTherapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.Adaptive Resistance to Cancer Immunotherapy.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules
P2860
Q26774913-862B1661-87B6-46EE-84F9-B7EAAC0909A1Q27006934-61866B44-6CF7-4C50-95F4-F33C0709E50EQ36430118-2D6F3062-2A98-41C2-A9CE-69AC7C451B19Q37058110-6DDC2E78-B9F0-4CBD-AA92-B68E7F43F2AEQ37071139-436E0014-A43C-4F86-A196-7FF21D7BD536Q38246639-631D9293-CE66-4D80-A9AD-62D5838B79F1Q38282541-2BB24AF9-9A37-4A22-BB02-229269B4F25CQ38445350-24891EDA-B9CD-4FAE-A404-E06166F76643Q38564461-A15FC3CF-32C5-4479-9B73-B5B89B75668FQ38766349-B1826912-1907-4061-A210-1F83E2141410Q39003786-FFE66826-2010-4A38-8E1B-33922C0A662CQ40890509-C6215271-7B49-4A23-B4D3-2CFF733E09F2Q47252744-7D07923E-AF78-4F87-9B37-9184CBBF0B44Q47348957-E0173DE2-F8F2-47B8-A537-93380700D21AQ47829053-8371FFF1-55F6-40EA-A63D-B4EE6E38A533Q57805467-08CCBC09-6F97-48E9-90A9-851F8220CB1F
P2860
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immune escape from NY-ESO-1-sp ...... of heterozygosity in the MHC.
@ast
Immune escape from NY-ESO-1-sp ...... of heterozygosity in the MHC.
@en
type
label
Immune escape from NY-ESO-1-sp ...... of heterozygosity in the MHC.
@ast
Immune escape from NY-ESO-1-sp ...... of heterozygosity in the MHC.
@en
prefLabel
Immune escape from NY-ESO-1-sp ...... of heterozygosity in the MHC.
@ast
Immune escape from NY-ESO-1-sp ...... of heterozygosity in the MHC.
@en
P2093
P2860
P356
P1433
P1476
Immune escape from NY-ESO-1-sp ...... of heterozygosity in the MHC.
@en
P2093
A M Towlerton
W I Bensinger
Z K Klippel
P2860
P2888
P304
P356
10.1038/GT.2013.87
P577
2014-01-23T00:00:00Z